Arbutus Biopharma
ABUS
ABUS
91 hedge funds and large institutions have $87.5M invested in Arbutus Biopharma in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 22 closing their positions.
Holders
91
Holders Change
-3
Holders Change %
-3.19%
% of All Funds
1.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
22
Reduced
25
Closed
22
Calls
$2.76M
Puts
$4.95M
Net Calls
-$2.19M
Net Calls Change
-$573K
Top Buyers
| 1 |
1
BlackRock
New York
|
$17.7M |
| 2 |
2
State Street
Boston,
Massachusetts
|
$3.5M |
| 3 |
3
Vanguard Group
Malvern,
Pennsylvania
|
$11.3M |
| 4 |
4
Geode Capital Management
Boston,
Massachusetts
|
$3.9M |
| 5 |
5
Northern Trust
Chicago,
Illinois
|
$2.18M |
Top Sellers
| 1 |
1
Renaissance Technologies
New York
|
$0 |
| 2 |
2
Morgan Stanley
New York
|
$884K |
| 3 |
3
Citadel Advisors
Miami,
Florida
|
$336K |
| 4 |
4
Millennium Management
New York
|
$0 |
| 5 |
5
Two Sigma Investments
New York
|
$769K |
